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Purpose: To investigate the influence of the Factor H (CFH) Tyr402His polymorphism on the plasma levels of the
alternative pathway proteins CFH, C3, Factor B (FB), Factor D (FD), and Factor I (FI) and the inflammatory marker C-
reactive protein (CRP) in 119 patients with age-related macular degeneration (AMD) and 152 unrelated control
individuals.
Methods: Patients with AMD and the control group were separated according to CFH polymorphism, age, and gender.
Plasma complement proteins and CRP concentrations were determined with enzyme-linked immunosorbent assay,
immunodiffusion, or nephelometry.
Results: Significant differences in the concentrations of FD and FI were observed between the patients with AMD and
the control individuals. We observed significantly reduced FD plasma levels in patients with AMD. We also identified
a significant decrease in CFH plasma levels in female patients with AMD in relation to female controls. Plasma FI
levels were significantly increased in patients with AMD compared to the control group. Regarding gender, a
significant increase in FI plasma levels was observed in male patients. Finally, we found no significant correlation
between the CFH Tyr402His polymorphism and the CFH, C3, FB, FD, FI, and CRP plasma levels.
Conclusions: Patients with AMD present altered levels of FD and FI in a manner independent of this CFH
polymorphism, and gender apparently contributes to the plasma levels of these two proteins in patients with AMD and
control individuals.
The complement system plays an important role in host
defense as a central component of innate and acquired
immunity [1,2] and is considered one of the most effective
protagonists of the immune and inflammatory responses [3].
An understanding of the complement system’s activation,
regulation, and effector mechanisms is important to guide
the search for new therapy targets for pathological
conditions. During homeostatic conditions, the complement
system is strictly regulated by soluble and cell membrane–
associated proteins. When deregulated, this system can
induce damage to host cells and consequently contribute to
the development of specific diseases and pathological
conditions such as certain autoimmune diseases,
glomerulonephritis [4] and hemolytic uremic syndrome [5].
The complement system is activated as a cascade by the
classical, alternative, or lectin pathways. The alternative
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pathway is continuously activated in vivo through
spontaneous C3 thioester bond hydrolysis, resulting in the
formation of C3 convertase, generating C3b, and other
activated proteins that mediate many biologic functions of
the complement system [2,6]. Factor H (CFH) is one of the
main regulators of the activation of the alternative pathway.
CFH prevents the formation of the C3 convertase enzyme
and promotes its dissociation. In addition, CFH acts as a
cofactor of the enzyme factor I (FI), mediating the
proteolytic inactivation of C3b [7].
The inflammatory response contributes effectively to
important diseases related to aging, including Alzheimer
disease and Parkinson disease [8], multiple sclerosis [9], and
atherosclerosis [10]. Recent studies have provided
increasing evidence that inflammation is an important
mechanism in age-related macular degeneration (AMD)
etiopathogenesis [11-13]. Furthermore, elevated levels of
serum C-reactive protein (CRP), a well known inflammation
marker, are associated with AMD [14].
AMD is the most common cause of irreversible visual
loss in the elderly population of the Western world [15].
This late-onset disorder severely undermines vision, causing
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progressive destruction of the macula, a noble region of the
retina, and a consequent loss of macular function and death
of photoreceptors cells [16]. AMD is characterized by the
presence of drusen, a focal deposition of extracellular
material underneath the retinal pigment epithelium. Despite
intensive investigation, many fundamental questions
regarding AMD pathogenesis remain unclear.
A breakdown of the blood–retinal barrier is observed in
neovascular patients with AMD and is associated with
retinal edema and the inflammatory repair process [17].
Under these conditions, complement circulating proteins
may reach the retinal region and may locally activate the
alternative pathway. Close regulation of this system is
essential to avoid continuous amplification of the
inflammatory process in the eye. Among the many different
substances encountered in the drusens of patients with AMD
are the complement proteins C1q, C3, C4, C5, CFH,
membrane cofactor protein, decay accelerating factor, the
anaphylatoxins C3a and C5a, immunoglobulins, CRP,
cholesterol esters, and low-density lipoprotein [18,19].
These results strongly indicate that the complement system
is activated in situ at the macula and if unregulated could
possibly contribute to inflammatory response in the eye.
Since 2005, numerous genetic studies have suggested
that AMD might be associated with the CFH Tyr402His
polymorphism, since homozygous individuals carrying the
variant CFH His402 are five to seven times more susceptible
to developing AMD [20-22]. Many of these studies
explored this association in an attempt to highlight the
mechanisms by which CFH can participate in the
pathogenesis of AMD. Recently, researchers have shown
that CFH is one of the most abundant proteins that bind to
malondialdehyde (MDA)—a common product of lipid
peroxidation generated after oxidative stress [23]. MDA
binds to local tissue proteins and may trigger an
inflammatory response as has been observed previously in
atherosclerosis [23] and AMD [24,25]. The variant CFH
His402 binds to MDA proteins less efficiently than CFH
Tyr402 and so could be a possible explanation for the higher
risk of developing AMD observed in individuals carrying
the variant CFH His402 [23].
Recently, we demonstrated that the CFH Tyr402His
polymorphism is a risk factor for developing AMD in
Brazilian patients: an odds ratio of 1.36 for patients carrying
only one 1277C allele (heterozygous CT; His/Tyr) and 4.63
for those carrying two 1277C alleles (homozygous CC; His/
His) compared to the control group [26].
Since the retinal region of patients with AMD may be
exposed to blood circulating proteins and activation of the
complement system could enhance the inflammatory
process, we decided to investigate if patients with AMD
with different CFH variants (Tyr402His) present differences
in the plasma levels of the complement alternative pathway
proteins CFH, C3, FB, FD, and FI. Because AMD is an
inflammatory disease, we also characterized the
inflammatory status of these patients by determining their
serum CRP levels.
MATERIALS
Human participants and plasma samples: Blood was
withdrawn using 0.34 M EDTA and after 30 min at room
temperature the samples were centrifuged and plasma
harvested and aliquot and kept at −80 °C until use. Blood
samples were obtained from a total of 119 patients with
AMD and 152 unrelated controls previously described in a
prospective investigation in which they were genotyped for
CFH Tyr402His polymorphism [26]. All participants were
over 50 years of age, underwent a complete ophthalmoscopy
examination, and provided informed consent for inclusion in
the study and the use of blood and DNA samples for
scientific purposes. The control subjects were examined
with a dilated fundus and selected if no signs of AMD or
other retinal disorders were detected. The study was
approved by the Ethics Committee for Human Research of
the Institute of Biomedical Sciences of the University of São
Paulo, São Paulo, Brazil.
Baseline characteristics of the investigated group
population have been described previously [26]. Mean ages
of the patients with AMD and controls were 73.3±9.1 and
71.7±9.7, respectively. Gender distribution was 39%
(46/119) male and 61% (73/119) female in the AMD group
and 34% (51/152) male and 66% (101/152) female in the
control group. No statistical difference was observed
between patients with AMD and controls with respect to age
or gender. The distribution of CFH phenotypes among
patients with AMD was significantly different from that
among the control subjects (χ2=22.025, p<0.001) [26].
Plasma levels of complement proteins and C-reactive
protein: Plasma levels of C3, FD, and FI were determined
with enzyme-linked immunosorbent assay (ELISA).
Microtiter plates (Costar, #3590, Corning, New York, NY)
were coated with a capture specific antibody for each
protein, using polyclonal rabbit anti-human C3, rabbit anti-
human FD, or monoclonal mouse anti-human FI as the
capture antibody (Calbiochem, Darmstadt, Germany). Goat
anti-human C3, anti-human FD, or anti-human FI
(Calbiochem) were used as secondary antibodies. Detection
was performed using an alkaline-phosphatase conjugated
antibody anti-goat immunoglobulin G (IgG) and p-
nitrophenyl phosphate (pNPP; Calbiochem) substrate.
Optical density was measured at 405 nm. The assay was
calibrated with different concentrations of purified C3, FD,
or FI proteins (Calbiochem). Plasma levels of FH and FB
were determined using a radial immunodiffusion protocol
[27]. Plasma levels of CRP were determined with
nephelometry.
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Statistical analysis: In all experiments, the AMD group was
compared to the control group. The categorical data between
the two groups were analyzed, and the Hardy–Weinberg
equilibrium was tested using the χ2 test. Numerical data
were examined using the Mann–Whitney test and ANOVA
(ANOVA) analysis. The significance level was set at
p<0.05. All data were expressed as the mean and standard
deviation.
RESULTS
We assessed whether the CFH Tyr402His polymorphism was
correlated with CFH plasma levels in patients with AMD
and control groups. The average concentration of this
regulatory protein was similar between the two groups
(653.2±194.3 µg/ml for patients with AMD;
628.6±182.2 µg/ml for the control group). No significant
differences in serum CFH levels were observed in the
different age groups (data not shown) or in the groups with
different CFH phenotypes (Table 1). We observed a small
but statistically insignificant difference between the AMD
and control groups in the gender distribution according the
levels of plasma CFH: men presented lower levels
(612.9±164.4 µg/ml) than women (678.5±208.2 µg/ml) in
the AMD group while in the control group, the opposite
relationship was observed (men: 645.9±196.8 µg/ml;
women: 619.9±174.8 µg/ml; Table 1). Similar results were
observed for plasma C3 levels. No differences were found
between the two main groups: 1.5±0.7 mg/ml for patients
with AMD and 1.6±1.0 mg/ml for the control group. No
significant differences were observed when we compared
C3 levels accordingly to CFH (Tyr402His) phenotype, gender
(Table 1), and age (data not shown). We extended this
analysis to other complement proteins involved in the
alternative pathway. No difference was observed in the FB
plasma levels of patients with AMD (303.5±111.0 µg/ml)
and the control group (315.4±101.9 µg/ml; Figure 1A).
However, we observed a significant increase in the FB
plasma levels in female patients with AMD compared to
male patients with AMD (327.7±115.9 µg/ml for women;
265.0±91.5 µg/ml for men, Figure 1B). No significant
differences in FB plasma levels were observed when the
individuals were classified by either CFH (Tyr402His)
phenotype (Figure 1C) or age (Figure 1D).
Plasma FD levels were significantly decreased in
patients with AMD (1.6±1.1 µg/ml for patients;
2.1±1.1 µg/ml, for controls) as shown in Figure 2A. In
addition, we found a significant difference in FD levels
between female patients and female controls while we did
not observe a significant difference in FD levels between the
male AMD and control groups (Figure 2B). No significant
differences were observed when the individuals were
classified by either CFH (Tyr402His) phenotype (Figure 2C)
or age (Figure 2D).
FI levels, on the other hand, were observed to be
significantly elevated in patients with AMD
(21.0±4.5 µg/ml) compared to controls (19.0±3.7 µg/ml,
Figure 3A). When we analyzed the FI levels according to
gender, we observed a significant difference between male
patients with AMD and male controls while observing no
significant difference in FI levels between the female AMD
and female control groups (Figure 3B). No significant
differences were observed when the individuals were
classified by either CFH (Tyr402His) phenotype (Figure 3C)
or age (Figure 3D). These data suggest that gender may
exert some influence on FD and FI plasma levels in patients
with AMD.
To investigate the association of the CFH Tyr402His
polymorphism with the systemic inflammatory response, we
determined the CRP levels of patients with AMD and
control subjects. In our study, most of the patients with
AMD presented normal levels of CRP. The CRP
concentrations were not statistically different between the
patients' and the controls' plasma levels. This parameter was
also not influenced by age, CFH Tyr402His phenotype, or
gender (data not shown).
Age does not seem to influence the concentrations of
the alternative pathway proteins that were analyzed.
However, for every age category, patients with AMD tend
to have higher FI and CRP levels than the control
individuals. However, no significant difference was found
between these groups in each age category. Furthermore, we
found no significant influence of the CFH Tyr402His
polymorphism on the plasma concentrations of the
alternative pathway proteins tested (Table 1).
DISCUSSION
The etiopathogenic factors of AMD have been studied
considerably in recent decades. Currently, AMD is defined
TABLE 1. PLASMA LEVELS OF FH, C3 AND CRP IN AMD PATIENTS AND CONTROLS ACCORDING TO FH PHENOTYPE AND GENDER.
 FH Phenotype                                                                                  
Gender
 
Y 402 Y 402H H 402 AMD  Control
Protein
(mg/ml)
AMD Control AMD Control AMD Control Male Female Male Female
CFH 0.7±0.2 0.6±0.1 0.7±0.1 0.6±0.2 0.7±0.2 0.6±0.1 0.6±0.2 0.7±0.2 0.6±0.2 0.6±0.2
C3 1.6±0.6 1.5±1 1.5±0.7 1.7±1.1 1.6±0.8 1.5±0.8 1.3±0.7 1.7±0.7 1.5±0.9 1.6±1.1
CRP 0.9±3.7 0.4±0.4 0.5±0.5 0.4±0.5 0.7±1.5 0.6±1.1 1± 3.2 0.5±0.5 0.4±0.5 0.5±0.6
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as a group of progressive degenerative changes that affect
patients over 50 years of age. AMD is clinically
characterized by the presence of drusens in the macula
[28,29], a crucial area of the retina responsible for central
vision.
The correlation between the CFH Tyr402His
polymorphism and AMD has previously been evaluated by
several groups [20-22]. An extensive study employing 4,484
patients with AMD and 5,736 controls from different
populations was recently published by Sivakumaran et al.
[29]. They suggested that a 32 kb region in CFH
downstream of rs1061170 (encoding His402Tyr) carries two
important single nucleotide polymorphisms with an even
stronger association with AMD risk than rs1061170:
rs139428 and rs203687 located in intronic regions of CFH.
Figure 1. Plasma factor B levels. The plasma factor B (FB) concentration in samples from 119 patients with age-related macular
degeneration (AMD) and 152 controls was determined with enzyme-linked immunosorbent assay (ELISA; A). The AMD patient group
was made up of 46 men and 73 women. In the control group, 51 were male and 101 female (B). FB levels are also classified according to
factor H (FH) polymorphism (C) and age (D). *p<0.05.
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We examined the CFH Tyr402His polymorphism in
Brazilian patients [30] and found odds ratios of 1.36 and
4.63 for patients with AMD carrying one or two alleles
(1277C; His402), respectively, compared to the control
group. Our results were similar to those observed in several
other populations from North America [20-22,31-33],
Europe [34-37], Asia [38-40], and Israel [41]. Due to the
ethnically heterogeneous characteristics of the Brazilian
population, identifying a genetic correlation with a disease
is of great importance.
Several groups have indicated that inflammatory
processes play an important role in the pathogenesis of
AMD [13]. As an important mediator of inflammation, the
complement system is potentially a major player in AMD
Figure 2. Plasma factor D levels. The plasma factor D (FD) concentration was determined with enzyme-linked immunosorbent assay
(ELISA) in samples from 119 patients with age-related macular degeneration (AMD) and 152 controls (A). The AMD patient group was
made up of 46 men and 73 women. In the control group, 51 were male and 101 female (B). FD levels are also classified according to factor
H (FH) polymorphism (C) and age (D). *p<0.05.
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pathology, an idea supported by the association of
polymorphisms of CFH with this disease. Moreover, CFH
and other complement proteins, CRP, and cholesterol have
been detected in the drusen isolated from the macular
region, the sub-retinal pigment epithelium space, and around
the capillaries of the choroids [20-22,42]. These
observations reinforce the hypothesis that local
inflammation along with altered regulation of the
complement system on the retina may contribute to the
development of AMD [42,43]. Other risk factors for AMD,
including smoking, hypertension, and obesity, have been
associated with reduced serum concentrations of CFH
Figure 3. Plasma factor I levels. The plasma factor I (FI) concentration was determined with enzyme-linked immunosorbent assay (ELISA)
in samples from 119 patients with age-related macular degeneration (AMD) and 152 controls (A). The AMD patient group was made up of
46 men and 73 women. In the control group, 51 were male and 101 female (B). FI levels are also classified according to factor H (FH)
polymorphism (C) and age (D). *p<0.05.
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[44-46], and subtle variations in plasma components of the
alternative pathway could have a significant impact on its
local activation in response to stimuli even though the
researchers found no differences between the AMD and
control groups regarding the CFH and C3 levels. The results
agree with the results of the present study (Table 1). Even
though the FD levels decreased and the FI levels increased
in the serum of patients with AMD compared to the control
group, our results indicate that the CFH Tyr402His
polymorphism does not interfere in the plasma
concentrations of the components of the alternative pathway
of complement activation.
Other studies have shown that the FB Arg32Gln
polymorphism is associated with a lower risk of developing
AMD [47-49]. Expression of FB increases with advancing
age in the apical region of the retinal pigment epithelium
[50]. In addition, FB levels may be influenced by the action
of tumor necrosis factor α (TNF-α) and interferon α (IFN-
α). An inverse relationship between FB and AMD
independent of genotype was observed by Reynolds et al.
[51]. When they assessed the interaction between genotype
and complement components, the researchers concluded that
this inverse relationship was valid only with the protective
FB genotype CC, but was unrelated to AMD risk with the
other FB genotypes (CT and TT). Little is known about the
concentration of FB in patients with AMD. High levels of
FB in patients with AMD compared to controls (mean
803 µg/ml for patients, ranging from 497 µg/ml to
1489 µg/ml; controls with an average of 642 µg/ml, ranging
from 378 µg/ml to 1354 µg/ml) have been reported [47]. In
our study group, however, we found no significant
difference in the plasma concentration of FB between the
groups. Moreover, the FB levels observed by Scholl et al.
[47] were much higher than those found in our study
population; our patients presented an average FB
concentration of 303±111 µg/ml while the control subjects
had an average of 315±102 µg/ml.
Our observations regarding FD levels were also
different from those observed by Scholl et al. [47]: patients:
1.26 µg/ml (0.69–2.30; this study: patients: 1.6±1.1 µg/ml),
controls: 0.95 µg/ml (0.50–1.65; this study: 2.0±1.1 µg/ml).
More recently, Stanton et al. [52] also observed that the FD
plasma concentration was increased in patients with AMD
compared to the control group. They also reported a genetic
association of a single nucleotide polymorphism rs3826945
and AMD, especially in female patients. FD is a single
polypeptide chain of 25 kDa that plays an important role in
amplifying the alternative pathway. This heat-labile enzyme
is present in the serum in active form [53], and the enzyme’s
function is to cleave FB, forming Ba and Bb. FD has an
essential role in the onset and amplification of the
alternative pathway. FD-deficient mice have a higher
vulnerability to retinal damage induced by exposure to
sunlight [54]. In addition, patients with total or partial FD
deficiency are rare and do not necessarily present higher
susceptibility to infection by several microorganisms
[55-57]. Recently, another group [58] reported the lack of
association between six FD single nucleotide
polymorphisms and genetic susceptibility to developing
advanced AMD. Considering these data along with our
results, it seems plausible that early development of AMD
may be triggered by an infectious process in susceptible
individuals due to imbalances in development and/or
regulation of the inflammatory response in which the
complement system has a major role [59-61]. However,
subtle alterations in activation efficiency and/or in a
regulatory capacity may contribute to the development of a
pathologic process that plays out over a span of several
years [51].
We observed significantly elevated FI levels in our
patients compared to the control group. FI is a soluble
88 kDa protein, responsible for the cleavage of C4b and
C3b. FI activity depends on cofactors such as C4BP, CFH,
CR1, and MCP. In addition, a polymorphism near the FI
gene has recently been associated with risk of advanced
AMD [62] and elevated expression of FI under the influence
of inflammatory cytokines such as interleukin-6 (IL-6),
IL-1, and TNF-α has been reported [63].
The cleavage of C3b is a central step in all three
activation pathways of the complement system. There is
some evidence that a polymorphism in the C3 (Arg120Gly)
gene increases the risk of developing AMD along with the
CFH Tyr402His polymorphism [64]. The presence of the C3
variant Arg80Gly was correlated to AMD [65]. Several
complement proteins such as C1q, C3, C4, C5, CFH,
membrane cofactor protein, decay accelerating factor, and
fragments C3a and C5a are commonly found in drusen,
AMD’s hallmark. Furthermore, recent data have suggested
these deposits stimulate local activation of the complement
system. This could lead to increased growth of deposits due
to the strong chemotactic activity that results from the
activation of certain fragments of the complement system
(e.g., C5a and C3a) and a marked influx of inflammatory
cells [66]. Higher plasma levels of Bb and C5a were
observed in patients with advanced AMD compared to
control individuals [51] confirming the continuous
activation of the alternative pathway during AMD. The
levels of these Bb and C5a fragments were not affected by
different gene polymorphisms (FH, FB, C2, C3, FD,FI, and
hypothetical gene LOC387715/age related maculopathy
susceptibility-2 [LOC387715/ARMS2]) described as related
to AMD risk. Amyloid substances present in the drusen of
patients with AMD have the ability to bind to FI, probably
inhibiting its activity in the complement regulatory cascade
in the same way that these substances bind to CFH [67].
Therefore, FI dysfunction could accelerate C3 convertase
generation, and the subsequent uncontrolled complement
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activation would lead to an intense local inflammatory
response.
The initial response of the immune system is triggered
by an infection or other offending agent and involves the
release of molecules such as cytokines (IL-12, TNF-α, IL-1)
and acute phase proteins [68,69]. CRP is an important acute
phase protein in humans and has been under investigation
because of its strong association with many inflammatory
diseases. This plasma protein plays a role in innate
immunity due to its ability to bind to microorganisms and
activate the complement cascade. The plasma concentration
of CRP usually does not exceed 0.1 mg/dL; however, this
value can rapidly increase during inflammation, tissue
injury, or extensive infectious processes, reaching 50 g/dl or
more, due to its increased synthesis by the liver [70].
CRP activates the classical pathway through its
interaction with C1q [71]. However, high levels of CRP
(>150 mg/ml) efficiently inhibit the activation of
complement [72]. CRP can also interact with CFH in a
manner dependent on Ca2+ [73], and this binding enhances
the regulatory ability of CFH in the alternative pathway,
preventing the formation of C3 and C5 convertases [74-78].
In addition, CRP could form a complex with C4BP [79],
acting as a FI cofactor, which in turn would degrade C4b
and reduce the activation of complement by the degradation
of C4b. Some studies [14,80-82] have correlated increased
plasmatic concentrations of CRP with progression of AMD
while others [21,83], including the present work, found no
significant difference between the concentrations of CRP
between patients with AMD and controls. The involvement
of CRP in AMD disease development therefore remains a
controversial issue.
Previous studies [81] have suggested that patients with
AMD carrying the variant CFH His402 presented a higher
CRP concentration locally in the eye than patients with the
variant CFH Tyr402. Furthermore, CRP has been consistently
found in drusen [79,81]. The CFH SCR 7 domain, where the
CFH Tyr402His polymorphism is located, is also the binding
site for CRP. The Tyr402His substitution could alter CFH’s
ability to bind to CRP and other ligands and perhaps affect
the level of local inflammation in the outer layers of the
retina [39]. A defective interaction between CRP and
complement factor H and factor H-like protein 1 is believed
to intensify the inflammatory cascade [19]. Johnson et al.
[81] have shown that individuals with the CFH His402
variant had higher levels of CRP in the choroid. Elevated
plasmatic CRP levels and reduced serum CFH associated
with obesity, hypertension, and smoking are considerable
risk factors for AMD [43-45,84]. In 2008, Kim et al. [40]
reported a correlation between plasma CRP and incidence of
AMD, although none of the known CRP polymorphisms
showed any correlation with the disease. These findings
reinforce the significance of CRP as a marker of
inflammatory disease processes but do not necessarily point
to the participation of this protein in the etiopathogenicity of
AMD. Local inflammation and immune-mediated events are
critical to the development of drusen [42,84,85]. In our
study, however, CRP levels remained normal in most
individuals, and we observed no difference between the
AMD and control groups. This leads us to conclude that we
cannot systemically associate CRP levels with development
of AMD.
In conclusion, we propose that the CFH Tyr402His
polymorphism does not influence the plasma levels of CFH
protein in patients with AMD or in the control group of
normal individuals and that this polymorphism does not
appear to be related to changes in the serum levels of other
components of the alternative pathway of complement.
However, patients and controls differ in the concentrations
of FD (reduced in patients with AMD) and FI (increased in
patients with AMD), which suggest some other factor
participates in activating the complement system in this
disease. Considering the i) high number of patients of this
study and ii) the strong ethnic mix observed in the Brazilian
population, differences observed in the plasma levels of
crucial proteins for activating the alternative pathway found
in patients with AMD may contribute to understanding the
role of the complement system in the pathogenesis of this
disease. As far as we know, this is the first study
investigating this kind of association in a highly ethnically
heterogeneous population.
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